Verily closed a $300 million funding round that reduced Alphabet’s ownership and ended its majority control of the healthcare‑focused unit. The Series X‑led capital infusion brings new outside investors and marks a governance shift for the life sciences arm that had been an Alphabet subsidiary. The lead sentence: Verily secured substantial outside capital and reorganized ownership to accelerate independent growth. The funding will support Verily’s product development in digital health, clinical research platforms and device commercialization at a time when life‑science tech companies seek scale and partnerships. The deal signals investor appetite for mature digital‑health assets with commercial prospects beyond parent‑company incubators. Market participants will watch how the new capitalization affects strategic partnerships, commercialization timelines, and the company’s ability to pursue independent M&A or alliances with biopharma customers.